📣 VC round data is live. Check it out!

OptimizeRx Valuation Multiples

Discover OptimizeRx's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Revium Recovery, Health Catalyst, Seer, Definitive Healthcare and more.

OptimizeRx Overview

About OptimizeRx

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.


Founded

2006

HQ

United States

Employees

129

Financials (LTM)

Revenue: $104M
EBITDA: $23M

EV

$105M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

OptimizeRx Financials

OptimizeRx reported last 12-month revenue of $104M and EBITDA of $23M.

In the same LTM period, OptimizeRx generated $71M in gross profit, $23M in EBITDA, and $19M in net income.

Revenue (LTM)


OptimizeRx P&L

In the most recent fiscal year, OptimizeRx reported revenue of $109M and EBITDA of $24M.

OptimizeRx is profitable as of last fiscal year, with gross margin of 67%, EBITDA margin of 22%, and net margin of 18%.

See analyst estimates for OptimizeRx
LTMLast FY202320242025202620272028
Revenue$104M$109M$72M$92M$109M
Gross Profit$71M$74M$43M$59M$74M
Gross Margin68%67%60%64%67%
EBITDA$23M$24M($21M)($9M)$17M
EBITDA Margin22%22%(30%)(10%)15%
EBIT Margin11%11%(24%)(7%)11%
Net Profit$19M$20M($18M)($20M)$5M
Net Margin18%18%(25%)(22%)5%
Net Debt-$2M---

Financial data powered by Morningstar, Inc.

OptimizeRx Stock Performance

OptimizeRx has current market cap of $101M, and enterprise value of $105M.

Market Cap Evolution


OptimizeRx's stock price is $5.38.

OptimizeRx share price increased by 3.7% in the last 30 days, and decreased by 60.0% in the last year.

OptimizeRx has an EPS (earnings per share) of $1.06.

See more trading valuation data for OptimizeRx
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$105M$101M3.7%3.7%-14.3%-60.0%$1.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

OptimizeRx Valuation Multiples

OptimizeRx trades at 1.0x EV/Revenue multiple, and 4.5x EV/EBITDA.

See NTM and 2027E valuation multiples for OptimizeRx

EV / Revenue (LTM)


OptimizeRx Financial Valuation Multiples

As of June 2, 2026, OptimizeRx has market cap of $101M and EV of $105M.

OptimizeRx has a P/E ratio of 5.3x.

LTMLast FY202320242025202620272028
EV/Revenue1.0x1.0x1.5x1.1x1.0x
EV/EBITDA4.5x4.3x(4.9x)(11.7x)6.3x
EV/EBIT9.3x8.7x(6.0x)(16.8x)8.7x
EV/Gross Profit1.5x1.4x2.4x1.8x1.4x
P/E5.3x5.1x(5.7x)(5.0x)19.7x
EV/FCF-5.6x(12.9x)23.5x5.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified OptimizeRx Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

OptimizeRx Margins & Growth Rates

OptimizeRx decreased revenue by 11% and EBITDA by 9% in the last fiscal year.

In the most recent fiscal year, OptimizeRx reported gross margin of 67%, EBITDA margin of 22%, and net margin of 18%.

See estimated margins and future growth rates for OptimizeRx

OptimizeRx Margins

Last FY202420252026202720282029
Gross Margin67%64%67%69%
EBITDA Margin22%(10%)15%23%
EBIT Margin11%(7%)11%11%
Net Margin18%(22%)5%19%
FCF Margin17%5%17%-

OptimizeRx Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(11%)29%19%(11%)
Gross Profit Growth(9%)38%24%(9%)
EBITDA Growth(9%)(58%)(286%)34%
EBIT Growth(15%)(65%)(294%)(15%)
Net Profit Growth(8%)14%(126%)255%
FCF Growth-(155%)322%-

Data powered by FactSet, Inc. and Morningstar, Inc.

OptimizeRx Operational KPIs

OptimizeRx's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.5M for the same period.

OptimizeRx's Rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

OptimizeRx's Rule of X is (5%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for OptimizeRx
LTMLast FY202320242025202620272028
Rule of 4020%12%---
Bessemer Rule of X17%(5%)---
Revenue per Employee-$0.8M---
Opex per Employee-$0.5M---
G&A Expenses to Revenue50%54%81%67%52%
Opex to Revenue-56%84%71%56%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Revium Recovery----
Health Catalyst0.5x0.6x4.0x4.4x
Seer(2.4x)(2.4x)1.0x1.1x
Definitive Healthcare0.4x0.4x1.4x1.5x
CareCloud0.9x0.9x3.8x3.8x
Alcidion Group3.6x2.9x27.0x21.5x
Oneview Healthcare6.1x5.6x(7.9x)(9.2x)
Fonet6.1x-12.4x-

This data is available for Pro users. Sign up to see all OptimizeRx competitors and their valuation data.

Start Free Trial

Acquisitions by OptimizeRx

OptimizeRx has acquired 4 companies to date.

Last acquisition by OptimizeRx was on October 12th 2023. OptimizeRx acquired Medicx Health for $95M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by OptimizeRx

Medicx Health
EvinceMed
RMDY Health
CareSpeak Communications
Description
-
EvinceMed is a provider of automation software for specialty pharmaceutical transactions. The platform streamlines prior authorizations, benefits verification, and hub services for oncology and rare disease drugs between manufacturers, payers, and providers.
RMDY Health is a Tel Aviv-based developer of digital therapeutics platforms for chronic disease management and wellness programs. The WellnessLayers app delivers personalized coaching for diabetes and hypertension, integrating wearables data for 100,000 users. RMDY Health partners with insurers like Clalit Health Services to deploy behavior change modules reducing HbA1c by 1.2 percent on average. Founded in 2018, the company operates in Israel and Europe with HIPAA-compliant cloud infrastructure.
CareSpeak Communications is a Somerset, New Jersey-headquartered provider of HIPAA-compliant digital health messaging platforms. It delivers patient engagement, medication adherence, and care coordination tools to insurers, pharmaceutical firms, pharmacies, and medical centers like Mount Sinai. The intelligent messaging system supports automated communications for chronic condition management.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
-
Las Vegas, NV
New York City, NY
Somerset, NJ
Deal Date12 Oct 202315 Mar 20225 Sep 201917 Oct 2018
Valuation$95M$12M$16M$9M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all OptimizeRx acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About OptimizeRx

When was OptimizeRx founded?OptimizeRx was founded in 2006.
Where is OptimizeRx headquartered?OptimizeRx is headquartered in United States.
How many employees does OptimizeRx have?As of today, OptimizeRx has over 129 employees.
Who is the CEO of OptimizeRx?OptimizeRx's CEO is Stephen L. Silvestro.
Is OptimizeRx publicly listed?Yes, OptimizeRx is a public company listed on Nasdaq.
What is the stock symbol of OptimizeRx?OptimizeRx trades under OPRX ticker.
When did OptimizeRx go public?OptimizeRx went public in 1996.
Who are competitors of OptimizeRx?OptimizeRx main competitors include Revium Recovery, Health Catalyst, Seer, Definitive Healthcare, CareCloud, Alcidion Group, Oneview Healthcare, Fonet, Apiam Animal Health, Champions Oncology.
What is the current market cap of OptimizeRx?OptimizeRx's current market cap is $101M.
What is the current revenue of OptimizeRx?OptimizeRx's last 12 months revenue is $104M.
What is the current revenue growth of OptimizeRx?OptimizeRx revenue growth (NTM/LTM) is (2%).
What is the current EV/Revenue multiple of OptimizeRx?Current revenue multiple of OptimizeRx is 1.0x.
What is the current EBITDA of OptimizeRx?OptimizeRx's last 12 months EBITDA is $23M.
What is OptimizeRx's EBITDA margin?OptimizeRx's last 12 months EBITDA margin is 22%.
What is the current EV/EBITDA multiple of OptimizeRx?Current EBITDA multiple of OptimizeRx is 4.5x.
How many companies OptimizeRx has acquired to date?As of June 2026, OptimizeRx has acquired 4 companies.
What was the largest acquisition by OptimizeRx?$95M acquisition of Medicx Health on 12th October 2023 was the largest M&A OptimizeRx has done to date.
What companies OptimizeRx acquired?OptimizeRx acquired Medicx Health, RMDY Health, EvinceMed, and CareSpeak Communications.
In how many companies OptimizeRx has invested to date?OptimizeRx hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to OptimizeRx

Lists including OptimizeRx

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial